IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

ORGAN-ON-A-CHIP: A COMPREHENSIVE REVIEW

[1]Nidhi Vichare, [2]Karun Jambhure, [3]Dr. Vimla Choudhari

[1&2] Student. B.Pharmacy School of Pharmacy D.Y. Patil University, Ambi, Pune.

[3]Assistant Professor, School of Pharmacy D.Y. Patil University, Ambi, Pune

[1] Pharmacy Department

[1] D.Y. Patil University School of Pharmacy, Ambi, Pune. Maharashtra. India

Abstract:

Organ-on-a-chip (**OOC**) technology is revolutionizing the fields of biomedical research and pharmaceutical development by providing advanced in vitro models that mimic the physiological functions of human organs. The present review is aimed at synthesizing studies relating to the current states, applications, and challenges of **OOC** systems. It has also driven the development of sophisticated **OOC** devices which better emulate complicated human organ functions made possible by the coming about of new microfabrication techniques such as 3D printing and photolithography, that could not be possible with the earlier cell culture and animal models. These have been paramount in drug discovery and toxicology testing, allowing improved predictive capability on drug efficacy and toxicity, which can be used to drastically reduce development costs and time in the pharmaceutical industry. It further outlines the review, if needed, to underline the fact that progress in **OOC** technology depended on close collaboration among engineering, biology, and clinical sciences. With all these developments under way, technical challenges in microfabrication, cell sourcing, standardization, and scalability remain to be overcome. This review paper aims at providing an elaborate look into the current state of **OOC** technology, involving device fabrication, biological applications, and translational possibility. This transformative impact is discussed by discussing key advancements, challenges and future directions for **OOC** systems on science and personalized medicine nowadays.

Key words: Organ-on-a-Chip, Microfabrication, Personalized Medicine, polydimethylsiloxane (PDMS)

1. Introduction:

1.1 Background and Significance:

Organ-on-a-chip **(OOC)** technology involves merging microengineering with biology to develop micro physiological systems that imitate human organ functions. Moreover, it overcomes conventional cell cultures' limitations as well as animal models in biomedical research hence generating more precise data which are relevant to humans in drug development processes. In this regard; the significance of **OOC** technology lies in its potentials for enhancing efficiency as well as predictability of drug testing; reducing reliance on animal models; allowing personalized treatment approaches. (1)

1.2 Historical Development:

The concept of scaling down complicated cellular systems into a small size and making them mimic human organ functions is one that found its way into the scientific fraternity early in the 2000s. It was, however, only after the realization of progress in microfabrication techniques, such as photolithography and soft lithography, that the concept took a practical turn. Most of the early models set a target on the replication of singular organs such as the liver and the heart. The technology has evolved over the years, and today it incorporates more complex systems capable of simulating interactions between multiple organs, sometimes called "Multi-Organ Chips" or "Body-on-a-Chip" systems. (1)

1.3 Importance and Applications

Conventional ways of studying human physiology and pharmacology have very limited potential by means of 2D cell cultures and animal models. The studies usually do not reproduce a human tissue environment and physiological responses regarding all details, which impacts their ability to translate from preclinical results to clinical trials. The **OOC** technology can therefore readdress these limitations by offering a much more physiologically relevant platform for assessing human biology. This has profound implications for several areas in biomedical research and industry:

1.3.1. Drug Discovery and Development:

OOC systems can provide a much more in vitro predictive model of new drug compound efficacy and toxicity. This is because these systems can closely replicate the human tissue environment to a large degree, generating data that has the potential to be highly representative of the way drugs will behave in the human body with a high accuracy of prediction; thus, potentially alleviating the high failure rates pertaining to drugs during clinical trials. (1)

1.3.2. Toxicology Testing:

Interest in **OOC** technology for toxicology testing is rapidly developing within regulatory agencies and the pharmaceutical industry. Traditional animal models far too often fail to predict human responses to toxins or drugs, causing alarmingly high rates of adverse effects discovered during clinical trials. While **OOC** models can provide more relevant data on human toxicology, they become important data for attaining regulatory approval and assessment of safety. (1)

1.3.3. Disease Modelling:

OOC devices have very successfully modelled a wide range of diseases at large depths and detailed the mechanisms behind such diseases, thus providing a lead toward targeted therapies. For example, lung-on-a-chip models have been applied to respiratory diseases and heart-on-a-chip models to cardiac diseases. Such models can also be person-specific using patient-derived cells and could open avenues for personalized medicine. (2)



(11)

2. Next-generation microfabrication techniques:

OOC technology has evolved commensurately with the development in microfabrication techniques. With 3D printing, photolithography, and soft lithography, one will work out the engineering of microfluidic channels within an **OOC** device and integrate sensors therein. Just these techniques can create complex tissue architectures with controlled microenvironments, a requirement for the successful recreation of organ functions. (2)

2.1. 3D Printing:

It has revolutionized the fabrication of **OOC** devices through the creation of intricate structures that replicate human tissues in spatial organization. This approach is useful for the construction of multi-layered structures and the generation of devices containing more than one cell type. (3)



(9)

2.2. Photolithography:

Photolithography is one of the processes used for patterning parts of a thin film or the bulk of a substrate and is key to creating the production of precise and scalable microfluidic channels. Being a technique already widely applied in the semiconductor industry, it was adopted for the manufacture of **OOC** devices, allowing high-resolution patterning and the possibility of integration of complex fluidic networks. (3)

2.3. Soft Lithography:

Soft lithography makes use of elastomeric materials, like **Polydimethylsiloxane (PDMS)**, for the creation of soft and biocompatible microfluidic devices. The technique can easily replicate microstructures and integrate dynamic features of mechanical stretch or fluid flow in a single device to reproduce physiological conditions. (3)

3. Problem Statement and Objectives and limitations:

The **OOC** technology, despite its potential, has challenges to overcome. These are technical limitations in microfabrication, sourcing viable human cells, lack of standardized protocols and regulatory barriers. This review aims at critically analysing the present state of **OOC** research, pointing out critical developments, assessing quality and outcomes of recent studies and discussing limitations as well as future endeavours. (4)

4. Technical Challenges in Microfabrication:

1) **Precision and Reproducibility:** Microfabrication is concerned with the highest precision and reproducibility in the production of microfluidic devices as one of the foremost technical challenges. Even though the methods such as 3D printing, photolithography, and soft lithography are very sophisticated, they are mostly ineffective in consistent or homogeneous microstructure production. Variability in the dimensions of the device can cause uneven results and cellular reactions and thus cancel out the value of the experimental results. (4)
2) **Integration of Functional Components:** The next main challenge is the combination of the different functional components like sensors and actuators into the required microfluidic devices. These devices in the **OOC** are critical in controlling- quality and quantity of nutrients and other gases. The fact that it is difficult to integrate these components without impacting the biological model by using proper engineering solutions is a general drawback. (4)
3) **Compatibility of Materials:** The key point is to make sure that the **OOC** devices used for the fabrication of these materials are compatible with the biology of the cells during cell culturing to stay away from adverse reactions owing to the biocompatibility requirement. 'Commonly used materials such as **polydimethylsiloxane (PDMS)'**, which are flexible and easy to produce, are some of the advantages of these materials, but on the other hand, they have a negative side: they are also capable of absorbing small molecules that are hydrophobic and that can lead to the jarring of the results of the drug tests or any other applications. (4)

5. Biological Challenges:

5.1. Cell Sourcing and Viability: The collection of viable human cells and their culture for the organ-on-chip system is a major hurdle. In-vitro technology is a key area of human stem cells research because of their success in producing biologically relevant results compared to immortalized cell lines. In-vitro opportunities for reproducible tissue and organ meteorological are presented by the availability of cellular tissue maintenance and culture of disease models. (5)

1) **Complex Tissue Engineering:** Regenerating the highly intricate physiology and function of human tissue in a lab dish is a monumental challenge. This involves a precise regulation of cellular differentiation, tissue organization, and the establishment of an efficient extracellular matrix medium. Achieving this intricacy is the necessary manoeuvre for taking an exact form of organ biology. (5)
2) **Vascularization:** One of the main components required for bioreactors that can emulate human organ systems are the regeneration of the vascular bed. The subsisting of microvasculature is a technology that is difficult to maintain. (5)

5.2 Standardization and Scalability: Lack of Standardized Protocols: The process of organ-on-a-chip fabrication is non-standardized. There is also the inconsistency in cell cultures and the experimental procedures they use. This variety results in discrepant data and creates obstacles in the comparison and replication of results across different laboratories. (6)

6. Quality and Outcomes of Selected Studies

The selected studies were divided into three main streams: device fabrication, biological applications and translational potential.

1. **Device Fabrication and Microfluidic Design**
    - The studies indicated novel microfabrication techniques, including 3D printing, photolithography, and soft lithography that are essential toward the production of physiologically relevant **OOC** models.
    - Some common problems were obtaining an accurate control over fluid flow as well as keeping cells alive. (7)



(10)

2. **Biological Applications and Cellular Responses**:
    - Different organs have been modelled (heart, liver, kidney, lung, brain), showing that **OOC** systems can mimic complex biological processes.
    - The results with **OOC** models showed an enhanced predictability for drug toxicity or efficacy testing compared to conventional methods. (8)
3. **Translational Potential and Drug Testing**:
    - There was a significant reduction in cost and time spent on drug development due to **OOC** technology which supplies more reliable human data earlier in the research process.
    - However, there was a need for standardization and scalability to accommodate wider use throughout the pharmaceutical industry. (8)

7. Results and Future Directions:

7.1. Advancing in Fabrication Innovation: Improving microfabrication methods used in **OOC**s is targeted for future research to enhance process control.

7.2. Improving the Biological Fidelity: To increase the biology fidelity of tissues models through generation and maintenance of primary human cells, rather than immortalized cell lines.

7.3. Interdisciplinary Community in Collaboration: To be advanced further, standardization of the experiment protocols and formation of interdisciplinary collaboration within the community is necessary.

7.4. Regulatory Milestones: Further growth and application to get formal regulatory approvals for moving **OOC** technologies to the market must proceed with an impact on patients with a diversity of conditions.

8. Conclusion

Organ-on-a-chip technology represents the new generation of biomedical research and holds out exciting potential for the future of discovering new drugs, mechanistic studies in toxicology, and for personalized medicine. While much work has been done, the way these challenges—technical, biological, and regulatory—are met will be significant for the future success and integration of **OOC** systems. Thus, innovation, interdisciplinary collaboration, and development of regulatory policies will need to be realized for the full benefit from this exciting new technology.

References:

1) Esch, E. W., Bahinski, A., & Huh, D. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248-260.
2) Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662-1668.
3) Huh, Dongeun, Geraldine A. Hamilton, and Donald E. Ingber. "From 3D cell culture to organs-on-chips." Trends in cell biology 21.12 (2011): 745-754.
4) Rossi, G., Manfredini, T., & Carulli, G. (2018). Organs-on-a-chip: 3D bioprinting in bioengineering. Journal of Tissue Engineering and Regenerative Medicine, 12(5), 1395-1409. Retrieved from Wiley Online Library
5) Bhatia, S. N., & Ingber, D. E. (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760-772.
6) Zhang, B., Korolj, A., Lai, B. F., & Radisic, M. (2018). Advances in organ-on-a-chip engineering. Nature Reviews Materials, 3(8), 257-278.
7) Williamson, Adam, et al. "The future of the patient-specific Body-on-a-chip." Lab on a Chip 13.18 (2013): 3471-3480.

8) AlShmmari, Sultan K., et al. "Hepatic spheroid-on-a-chip: Fabrication and characterization of a spheroid-based in vitro model of the human liver for drug screening applications." Biomicrofluidics 18.3 (2024).
9) Bosmans, C., Rodriguez, N.G., Karperien, M., Malda, J., Teixeira, L.M., Levato, R. and Leijten, J., 2024. Towards single-cell bioprinting: micropatterning tools for organ-on-chip development. Trends in biotechnology, 42(6), pp.739-759.
10) https://heal.nih.gov/news/stories/Human-on-a-Chip
11) https://www.mdpi.com/1999-4923/13/10/1657#